Ovid Therapeutics stock analysis
Want to see OVID full AI Analyst Report?
Ovid Therapeutics (OVID) Stock Price & Analysis
OVID Stock Chart & Stats
- Day’s Range
- $2.19 - $2.38
- 52-Week Range
- $1.21 - $3.11
- Previous Close
- $2.26
- Volume
- N/A
- Average Volume (3M)
- 2.34M
- Market Cap
- $441.63M
- Enterprise Value
- $381.28M
- Total Cash (Recent Filing)
- $136.60M
- Total Debt (Recent Filing)
- $12.35M
- Price to Earnings (P/E)
- ―
- Beta
- 1.71
- Next Earnings
- Mar 15, 2027 (Est.)
- EPS Estimate
- -0.1
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low debt relative to equity limits interest and refinancing pressure, preserving financial flexibility for clinical development and partnerships. This balance-sheet structure gives Ovid more capacity to absorb operating volatility than a highly leveraged biotech, provided losses do not continue eroding equity.
Asset Base
A sizable asset base provides a financial cushion while Ovid advances its pipeline through clinical development. That resource base can support operations and preserve strategic options over the next several quarters, although its durability ultimately depends on the pace of cash consumption and loss reduction.
Rare-neurology Focus
A focused pipeline in rare neurological and neurodevelopmental disorders can support specialized scientific expertise and clearer therapeutic positioning. Concentration in these areas may help Ovid build differentiated development capabilities and pursue partnership opportunities around unmet medical needs over time.
Bears Say
Persistent Cash Burn
Sustained negative operating and free cash flow means Ovid is consuming substantial resources to fund its business rather than self-financing operations. Continued burn can reduce the balance-sheet cushion and increase reliance on existing cash or future financing as clinical work proceeds.
Deep Operating Losses
Minimal revenue alongside a large net loss indicates that Ovid has not yet established durable earnings power. Persistent losses can weaken equity over time, constrain investment flexibility, and make progress dependent on successful development milestones or additional funding.
Revenue Volatility
Volatile and declining revenue makes Ovid’s financial base difficult to forecast and underscores its dependence on episodic collaboration-related income rather than recurring product sales. This reduces visibility into funding capacity and leaves results sensitive to development and partnership timing.
Ovid Therapeutics News
OVID FAQ
What was Ovid Therapeutics’s price range in the past 12 months?
What is Ovid Therapeutics’s market cap?
When is Ovid Therapeutics’s upcoming earnings report date?
How were Ovid Therapeutics’s earnings last quarter?
Is Ovid Therapeutics overvalued?
Does Ovid Therapeutics pay dividends?
What is Ovid Therapeutics’s EPS estimate?
How many shares outstanding does Ovid Therapeutics have?
What happened to Ovid Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ovid Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Ovid Therapeutics Stock Smart Score
Company Description
Ovid Therapeutics
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Margaret Alexander
- Employees
- 23
- Website
- www.ovidrx.com
- Address
- Hudson Commons, New York City, NY, 10001, US
Ovid Therapeutics (OVID) Earnings & Revenues
OVID Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |











